Navigation Links
Intellect Neurosciences Adds Two New Tau Programs to its Alzheimer's Disease Development Pipeline
Date:5/7/2012

udes therapeutic vaccines, antibodies and neuroprotective antibody drug conjugates.

The company currently is developing products based on three platform technologies: ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology, which underlies a product in Phase 3 clinical trials and is licensed to major pharmaceutical companies. ANTISENILIN also underlies IN-N01, a humanized monoclonal antibody being developed by the company as an antibody dug conjugate (ADC). IN-N01-OX2 is the first candidate to emerge from the company's CONJUMAB-A platform technology, which is based on a novel application of antibody drug conjugates in which the antibody is chemically conjugated to a small molecule (OX2) that has potent neuroprotective properties both as an antioxidant and inhibitor of protein aggregation. RECALL-VAX is a therapeutic vaccine technology that underlies three preclinical drug candidates, RV01 and RVO2, which target beta amyloid and delta tau protein, respectively, and RVO3 which is a combination of the two.

The company recently licensed OX1, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich's Ataxia and other neurodegenerative diseases. For more information, please visit www.intellectns.com.

Safe Harbor Statement Regarding Forward-Looking Statements:

The statements in this release and oral statements made by representatives of Intellect Neurosciences relating to matters that are not historical facts (including, without limitation, those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward-looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related biology technology :

1. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate
2. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
3. Intellectual Property Lawyer Available for Comment on Recent Supreme Court Ruling
4. Intellect Neurosciences, Inc. to Present at 10TH Annual BIO Investor Forum
5. PharmacoFore, Inc. Announces Appointment of Chief Medical Officer and Vice President of Intellectual Property
6. Ontario Institute for Cancer Research Announces Enhancements to its Intellectual Property Development and Commercialization Program
7. iPierian Expands Leadership Team With Experienced Business Development and Intellectual Property Executives
8. Intellect Neurosciences, Inc. Announces Preliminary Agreement with Significant Shareholders to Provide Interim Funding and Assist the Company in Efforts to Secure Additional Financing
9. China YCT International Group, Inc. Announces That the State Intellectual Property Office of the Peoples Republic of China has Approved a Patent to its Operating Subsidiary, Shandong Spring Pharmaceutical Co. Ltd.
10. BIO Ventures for Global Health Chosen to Administer the GSK and Alnylam Intellectual Property Pool
11. Joint BioEnergy Institute Selects Surety's AbsoluteProof to Protect the Integrity and Legally Defend the Authenticity of its Scientific Intellectual Property
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... The Formulate Fusion Fabric Display ... and marketing teams looking for a fully-functional package for their ... “everything you’ll need to put together a stunning and eye-catching ... a number of displays and accessories that can be quickly ... 20 feet in size. These components vary from kit to ...
(Date:5/20/2013)... -- , Collaboration with the U.S. ... in treatment of mastitis , Major ... begin in the second half 2013 ... Limited (ASX: POH, OTCQX: PPGNY) will collaborate with ... (ARS) to develop and trial products targeting the serious ...
(Date:5/20/2013)... Pa (PRWEB) May 20, 2013 Oven ... with ramp/soak capabilities. The 5R6-900 benchtop controller has ... the device can be plugged into the wall as ... power supply. This distinctive detail makes the device unique, ... , The laboratory temperature controller can also be used ...
(Date:5/20/2013)... -- Today, at the American Psychiatric Association (APA) Meeting ... James McGough , M.D., M.S., principal investigator and ... Neuroscience and Human Behavior and David Geffen ... California Los Angeles (UCLA), and director of clinical teaching ... at UCLA, presented the results of a Phase I ...
Breaking Biology Technology:GLM Displays Announces All-in-One Formulate Fusion Fabric Display Kit 2Phosphagenics Signs Research Agreement with the Agricultural Research Service 2New Laboratory Temperature Controller by Oven Industries 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 2Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 3Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 4Positive Results Reported for Phase I Clinical Trial at UCLA for the Treatment of ADHD in Children Using External Trigeminal Nerve Stimulation (eTNS) 5
... Importance of Allergy Testing in Managing Chronic ... ... Phadia US Inc. announced today,that The National Asthma Education and Prevention ... for the Diagnosis and,Management of Asthma. Information in the guidelines reported ...
... steps ... towards public reporting status., SAN ANTONIO, Aug. 30 ... targeted cancer therapies with improved efficacy and reduced toxicity,announced the ... a control position in a public reporting shell company. ...
... Aug. 30 Pressure,BioSciences, Inc. (Nasdaq: ... has been,issued its first patent by the ... Biomolecular Complexes" (Number,2,259,318), this issuance extends the ... patents previously issued in the United States,Japan, ...
Cached Biology Technology:Updated NIH Guidelines Offer Valuable Information on Asthma Diagnosis and Management 2OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company 2Pressure BioSciences, Inc. Issued First Patent in Canada 2Pressure BioSciences, Inc. Issued First Patent in Canada 3
(Date:5/21/2013)... is an uphill battle? Try staying fit in space, ... muscle and bone. , That,s the challenge a group ... new three-year, $1.2 million grant from NASA. Their goal ... exploratory missions. , "You could give astronauts the best ... them to stick to it, it isn,t going to ...
(Date:5/21/2013)... Royal Philips Electronics (NYSE: PHG, AEX: PHIA) ... ultrasound with Philips, industry leading Live 3D TEE, now ... with available Live 3D TEE and ICE will be ... EuroPCR, official meeting for the European Association of Percutaneous ... launch in 2012, Philips CX50 xMATRIX has been the ...
(Date:5/20/2013)... The Amazon rain forest, popularly known as the lungs of ... use carbon dioxide from the air to grow parts that ... away by the region,s plentiful rainfall. , Until recently ... the Amazon River and ended up deep in the ocean. ... exhale huge amounts of carbon dioxide though left open ...
Breaking Biology News(10 mins):Fueling fitness on the final frontier 2Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Amazon River exhales virtually all carbon taken up by rain forest 2Amazon River exhales virtually all carbon taken up by rain forest 3
... Kimmel Award for Innovative Investigation on Monday, Nov. 5 at ... grant of a million dollars over five years. Taking ... the impulses that drive evolution. Living cells are, from this ... have all sorts of interesting consequences for many other molecules ...
... all" when it comes to weight loss through exercise, says ... Neil King, from QUT,s Institute of Health and Biomedical Innovation, ... with the University of Leeds in the UK, which has ... of Obesity. "When it comes to losing weight, a ...
... issue of BioScience describes the history and summarizes the ... surface and substrate. , Although more expensive to construct ... energy costs during a buildings lifetime and control storm-water ... structures are currently less common in the United States ...
Cached Biology News:Weizmann Institute scientists discover: A 'risk distribution law' for evolution 2Weight loss -- not one size fits all 2
Normal human serum collected off the clot from healthy normal humans. Each donor unit is negative for anti-HIV 1&2, HIV-Ag, HCV, and HBsAg by FDA required tests...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Recombinant Mouse MMP-9, CF...
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: